Vandenbroucke JP - Search Results

1

Re-using Mini-Sentinel data following rapid assessments of potential safety signals via modular analytic programs.

Toh S, Avorn J, D'Agostino RB Sr, Gurwitz JH, Psaty BM, Rothman KJ, Saag KG, Sturkenboom MC, Vandenbroucke JP, Winterstein AG, Strom BL. Toh S, et al. Among authors: vandenbroucke jp. Pharmacoepidemiol Drug Saf. 2013 Oct;22(10):1036-45. doi: 10.1002/pds.3478. Epub 2013 Aug 7. Pharmacoepidemiol Drug Saf. 2013. PMID: 23922322

2

RE: Drug risk assessment and data reuse.

Toh S, Avorn J, D'Agostino RB Sr, Gurwitz JH, Psaty BM, Rothman KJ, Saag KG, Sturkenboom MC, Vandenbroucke JP, Winterstein AG, Strom BL. Toh S, et al. Among authors: vandenbroucke jp. Pharmacoepidemiol Drug Saf. 2014 Jan;23(1):109-10. doi: 10.1002/pds.3525. Pharmacoepidemiol Drug Saf. 2014. PMID: 24395550 No abstract available.

3

Opportunities for enhancing the FDA guidance on pharmacovigilance.

Psaty BM, Vandenbroucke JP. Psaty BM, et al. Among authors: vandenbroucke jp. JAMA. 2008 Aug 27;300(8):952-4. doi: 10.1001/jama.300.8.952. JAMA. 2008. PMID: 18728269 No abstract available.

4

Benefits and risks of drug treatments: how to combine the best evidence on benefits with the best data about adverse effects.

Vandenbroucke JP, Psaty BM. Vandenbroucke JP, et al. JAMA. 2008 Nov 26;300(20):2417-9. doi: 10.1001/jama.2008.723. JAMA. 2008. PMID: 19033592 No abstract available.

5

Association of the alpha-adducin polymorphism with blood pressure and risk of myocardial infarction.

Psaty BM, Doggen C, Vos HL, Vandenbroucke JP, Rosendaal FR. Psaty BM, et al. Among authors: vandenbroucke jp. J Hum Hypertens. 2000 Feb;14(2):95-7. doi: 10.1038/sj.jhh.1000943. J Hum Hypertens. 2000. PMID: 10723114

6

Instrumental variable analysis as a complementary analysis in studies of adverse effects: venous thromboembolism and second-generation versus third-generation oral contraceptives.

Boef AG, Souverein PC, Vandenbroucke JP, van Hylckama Vlieg A, de Boer A, le Cessie S, Dekkers OM. Boef AG, et al. Among authors: vandenbroucke jp. Pharmacoepidemiol Drug Saf. 2016 Mar;25(3):317-24. doi: 10.1002/pds.3956. Epub 2016 Jan 8. Pharmacoepidemiol Drug Saf. 2016. PMID: 26749045

7

A mapping between interactions and interference: implications for vaccine trials.

VanderWeele TJ, Vandenbroucke JP, Tchetgen EJ, Robins JM. VanderWeele TJ, et al. Among authors: vandenbroucke jp. Epidemiology. 2012 Mar;23(2):285-92. doi: 10.1097/EDE.0b013e318245c4ac. Epidemiology. 2012. PMID: 22317812 Free PMC article.

8

What is the best evidence for determining harms of medical treatment?

Vandenbroucke JP. Vandenbroucke JP. CMAJ. 2006 Feb 28;174(5):645-6. doi: 10.1503/cmaj.051484. CMAJ. 2006. PMID: 16505461 Free PMC article. No abstract available.

9

Observational research and evidence-based medicine: What should we teach young physicians?

Vandenbroucke JP. Vandenbroucke JP. J Clin Epidemiol. 1998 Jun;51(6):467-72. doi: 10.1016/s0895-4356(98)00025-0. J Clin Epidemiol. 1998. PMID: 9635995 Review. No abstract available.

10

Evidence-based medicine and "médecine d'observation".

Vandenbroucke JP. Vandenbroucke JP. J Clin Epidemiol. 1996 Dec;49(12):1335-8. doi: 10.1016/s0895-4356(96)00295-8. J Clin Epidemiol. 1996. PMID: 8970481 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

510 results

Search Page